Dr. Grint was most recently CEO and a member of the board of directors of AmpliPhi Biosciences, which recently merged with C3J Therapeutics to form Armata Pharmaceuticals. Prior to his role as CEO at AmpliPhi, Dr. Grint was the president and CEO of Regulus Therapeutics, Inc., a company focused on the discovery and development of microRNA therapeutics.
Dr. Grint has more than two decades of experience in biologics and small-molecule research and development, including the successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas. He has also served in senior management roles at Cerexa, Forest Laboratories, Kalypsys, Pfizer, IDEC Pharmaceuticals and Schering-Plough Corporation, and is currently a board member at Inhibikase Therapeutics and Synedgen.
Dr. Grint is a Fellow of the Royal College of Pathologists, and a member of numerous professional and medical societies. He holds a bachelor’s degree from St. Mary’s Hospital College, University of London, and a medical degree from St. Bartholomew’s Hospital College, University of London.